Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

The acquisition would significantly boost Novartis’ position in rare kidney disease IgA nephropathy (IgAN), which the Swiss big pharma is targeting with oral complement factor B inhibitor ...

On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; planning for Biologics License Application (BLA) submission for ...

Organic TFTs are shaking up the display world, offering flexible new design possibilities that challenge the long-standing dominance of amorphous-silicon transistors. OTFTs vs. a-Si transistors ...

Presently, there are many younger artists. One I am constantly reminded of is Igan D’Bayan as one of his “Headshot” series, oil on canvas, hangs right beside the main door of my son Vernon ...

In the ever-dynamic and fast-moving world of semiconductors, why do some old transistors like 2N3904 keep on going for decades? Bill Schweber takes a closer look at this remarkable premise while ...

Chinese researchers at Peking University have unveiled a potentially game-changing silicon-free transistor, claiming it could outperform the latest chips from Intel, TSMC, and Samsung. The ...

JADE101: potentially best-in-class anti-APRIL monoclonal antibody for IgAN First-in-human clinical trial anticipated to begin in the second half of 2025 with interim data expected in the first half of ...

We remain dedicated to working with our partners, regulators, and healthcare providers to expand access and improve outcomes for those affected by IgAN.” “The decision by the European ...

Guitars “This golden gain machine covers the entire spectrum from gritty boost through to full-on fuzz”: Great Eastern FX’s Focus Fuzz Deluxe has got boost, drive, octave, fuzz... everything going on ...